Skip header and navigation

Narrow By

   MORE

2 records – page 1 of 1.

Cancer Screening in Inflammatory Bowel Disease : A Guide to Risk Management and Techniques

https://libcat.nshealth.ca/en/permalink/provcat44388
Joseph D. Feuerstein, Adam S. Cheifetz, editors. --Cham: Springer , c2019.
Available Online
View e-Book
Location
Online
This book provides a concise, yet comprehensive overview of cancer risks in patients with inflammatory bowel disease (IBD), as well as the screening modalities used to reduce these risks. Each chapter presents a major malignancy that patients with IBD are at risk from, stemming from the disease itself or from the medications used to treat the disease. Malignancies covered include colorectal cancer, skin cancer, lymphoma, and other cancers. Cancer risk and screening with current and emerging dru…
Available Online
View e-Book
Other Authors
Feuerstein, Joseph D.
Cheifetz, Adam S.
Responsibility
Joseph D. Feuerstein, Adam S. Cheifetz, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2019
Physical Description
1 online resource (xi, 174 p.) : 14 illus. in color
ISBN
9783030153014
9783030153007 (Print ed.)
9783030153021 (Print ed.)
9783030153038 (Print ed.)
Subjects (MeSH)
Colorectal Neoplasms - diagnosis
Inflammatory Bowel Diseases - complications
Risk Factors
Specialty
Gastroenterology
Medical Oncology
Abstract
This book provides a concise, yet comprehensive overview of cancer risks in patients with inflammatory bowel disease (IBD), as well as the screening modalities used to reduce these risks. Each chapter presents a major malignancy that patients with IBD are at risk from, stemming from the disease itself or from the medications used to treat the disease. Malignancies covered include colorectal cancer, skin cancer, lymphoma, and other cancers. Cancer risk and screening with current and emerging drug therapies are also discussed. Written by experts in the field, Cancer Screening in Inflammatory Bowel Disease: A Guide to Risk Management and Techniques is a valuable resource for gastroenterologists, colorectal surgeons, and primary care physicians who treat and manage patients with inflammatory bowel disease.
Contents
Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases -- Screening for Colon Cancer in Inflammatory Bowel Disease -- Skin Cancer Risk and Screening in Patients with Inflammatory Bowel Disease -- Female Specific Cancern Risks and Screening in Inflammatory Bowel Disease -- Lymphoma Risk and Screening in Inflammatory Bowel Disease -- Pouch Neoplasia following IPAA in Patients with Underlying Inflammatory Bowel Diseases -- Other Cancers: Small Bowel Cancers, Cholangiocarcinoma, Urinary Tract, and Anal Cancer Risk and Screening in Inflammatory Bowel Disease -- Cancer Risks and Screening with Current and Emerging Drug Therapies in Inflammatory Bowel Diseases -- Preventing Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Chemopreventive and Surgical Approaches -- Cancer Risk and Screening in Pediatric Patients -- Colorectal Cancer Risk and Screening in Geriatric Patients -- Use of Biologic Drugs Following an Initial Diagnosis of Malignancy.
Format
e-Book
Location
Online
Less detail

Treatment of Inflammatory Bowel Disease with Biologics

https://libcat.nshealth.ca/en/permalink/provcat42935
edited by Adam S. Cheifetz, Joseph D. Feuerstein. --Cham, Switzerland: Springer , c2018.
Available Online
View e-Book
Location
Online
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment …
Available Online
View e-Book
Other Authors
Cheifetz, Adam S.
Feuerstein, Joseph D.
Responsibility
edited by Adam S. Cheifetz, Joseph D. Feuerstein
Place of Publication
Cham, Switzerland
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xi, 335 p.) : 22 illus., 19 illus. in color
ISBN
9783319602769
9783319602752 (print ed.)
9783319602776 (print ed.)
9783319868233 (print ed.)
Subjects (MeSH)
Anti-Inflammatory Agents - therapeutic use
Biological Products - therapeutic use
Inflammatory Bowel Diseases - drug therapy
Specialty
Biological Therapy
Gastroenterology
Abstract
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
Contents
Mechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn's Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn's Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics—Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies.
Format
e-Book
Location
Online
Less detail